SDS Optic S.A. creates and develops diagnostic and monitoring solutions, combining optoelectronics (photonics) with molecular biology, medical bioengineering and immunochemistry.
The mission of SDS Optic S.A. is one of the main objectives that many countries and international organizations have committed themselves to achieving. On 4 February 2017, on World Cancer Day, the World Health Organization published a new list of recommended medical procedures and services, that are required at an early stage of cancer development, to increase the chances of curing the patients.
According to the WHO, it is necessary to intensify the global development of diagnostic solutions that can be applied at the very beginning of the diagnostic pathway for people with suspected cancer.
Many countries have committed themselves to the Sustainable Development Goals (SDGs). One of the points of this agenda is to reduce premature deaths caused by cancer by 1/3 by 2030.
Our mission and objectiveis to increase the survivalof cancer patientsby 30% by 2030.
WHO is not the only international institution that, like SDS Optic, wishes to fight for the life of cancer patients. The objective of improving the quality of life and extending the life expectancy of 3 million people by 2030 through prevention and treatment, and supporting cancer patients and their families, was also included in the European Commission’s Horizon Europe document.
SDS Optic S.A. consciously the mission of increasing cancer survival by 30% by 2030 in its DNA. Research, reports and the direction of development of global and renowned organizations indicate that effective solutions for the diagnosis of diseases at the earliest possible stage can save human life and health.
That’s why we created inPROBE – a micron optical biosensor for the detection of bioelements in real time, in vivo (inside the human body). You can find more on how our technology works at https://inprobe.com/.